Synapse - Andrew Zelenetz

Search Within

Andrew D Zelenetz

Results (785)

Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin

Meeting Abstract

Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
Blood (2024)

Fulltext@MSK | Save

Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial

Meeting Abstract

Falchi, L.; Okwali, M.; Ferreira Lopes, A.; Hamlin, P. A.; Lue, J. K.; Ghione, P.; Owens, C.; Torka, P.; Kumar, A.; Steiner, R.; more...
Blood (2024)

Fulltext@MSK | Save

Tumor determinants of response to CAR-T therapy in relapsed or refractory mantle cell lymphoma

Meeting Abstract

Epstein-Peterson, Z. D.; Ryan, C. E.; Devlin, S. M.; Accav, N. G.; Avigdor, A.; Corona, M.; Danylesko, I.; Dela Cruz, J.; Goy, A.; Jacobson, C. A.; more...
Blood (2024)

Fulltext@MSK | Save

Treatment patterns and outcomes following progression of disease post-CAR-T therapy in relapsed or refractory mantle cell lymphoma: A multicenter analysis

Meeting Abstract

Epstein-Peterson, Z. D.; Lionel, A. C.; Joseph, A.; Drill, E.; Atallah-Yunes, S. A.; Brooks, T. R.; Chong, E. A.; Chong, E. R.; Dela Cruz, J.; Frank, M. J.; more...
Blood (2024)

Fulltext@MSK | Save

Molecular features are associated with disease stage in diffuse large B-cell lymphoma and reveal heterogeneity in patient outcomes

Meeting Abstract

Uppal, M.; Gurumurthi, A.; Hamlin, P. A.; Falchi, L.; Horwitz, S.; Kumar, A.; Noy, A.; Lue, J. K.; Torka, P.; Arcila, M. E.; more...
Blood (2024)

Fulltext@MSK | Save

Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma

Meeting Abstract

Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
Blood (2024)

Fulltext@MSK | Save

Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Updated safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study

Meeting Abstract

Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; more...
Oncology Research and Treatment (2024)

Fulltext@MSK | Save

A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma

Correspondence

Gurumurthi, A.; Bantilan, K. S.; Hamlin, P. A.; Kumar, A.; Matasar, M.; Zhu, M.; Joseph, A.; Castro, A.; Biggar, E.; Salles, G.; more...
Leukemia and Lymphoma (2024)

Fulltext@MSK | Save

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

Research Letter

Lue, J. K.; Luttwak, E.; Rivas-Delgado, A.; Irawan, H.; Boardman, A.; Caron, P. C.; David, K.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; more...
Blood Cancer Journal (2024)

Fulltext@MSK | Save

The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study

Journal Article

Zelenetz, A. D.; Jurczak, W.; Ribrag, V.; Linton, K.; Collins, G. P.; Jiménez, J. L.; Bishton, M.; Dholaria, B.; Mengarelli, A.; Phillips, T. J.; more...
HemaSphere (2024)

Fulltext@MSK | Save